Equaly Sa
Equaly is a discovery-stage biotechnology company, dedicated to leverage the role of a newly discovered type of Natural Killer T (“NKT”) cells to propose an innovative immunological approach to fight and eliminate tumour cells. Based on a newly discovered population of NKT lymphocytes, that can be activated by specific antigen through the same mechanism for everyone, allowing allogenic applications, Equaly develops innovative therapies that have the potential to revolutionise the treatment of cancers by offering a safer, more effective, and more affordable option than current therapies. Using the dynamic of the very same NKT cells, Equaly also develops non-immunogenic versions of existing Enzyme Replacement Therapies against metabolic orphan diseases.
7-day free trial · no credit card
Verified contacts
4
available on Kipplo
LinkedIn employees
3
1 to 10 range
Open roles
—
no listings
Distinct roles
4
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 4 verified contacts at Equaly Sa
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
4 contacts with verified email or phone · masked until revealed.
No verified contacts on record for this company yet.
Top roles at Equaly Sa
4 distinct titles indexed · top 4 shown.
- 1chief business officer
- 1founder - cso
- 1project director
- 1research assistant
Sign up to unlock all 4 contacts at Equaly Sa
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 4 verified contacts at Equaly Sa
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.